StockNews.com Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Price Performance

Shares of GLMD opened at $2.75 on Monday. The firm has a fifty day moving average price of $2.86 and a 200 day moving average price of $3.62. The stock has a market cap of $1.77 million, a PE ratio of -0.17 and a beta of 0.66. Galmed Pharmaceuticals has a 1-year low of $2.23 and a 1-year high of $23.80.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is owned by institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.